ClinicalTrials.gg
TerminatedNCT04970953DEST-HFUpdated May 11, 2023

Diastolic Exercise Stress Testing in Heart Failure

An observational study in Heart Failure With Preserved Ejection Fraction, sponsored by University Hospital, Essen. Terminated at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-11.

Sponsored by University Hospital, Essen · Observational

Why this study was terminated
We raised ethical concerns to proceed an invasive study despite having shown the expected results after 19 patients.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
19
Ages
18 Years and older
Sex
All
01

Study summary

Patients with an intermediate risk (HFA-PEFF score 2-4 points) for heart failure with preserved ejection fraction (HFpEF) will be further investigated with invasive right heart catheterization. All patients with a resting pulmonary artery wedge pressure (PAWP) \<15mmHg will undergo the following stress test modalities in a randomized order: (1) bicycle ergometry, (2) dynamic handgrip exercise, (3) 500ml fluid challenge over 5 minutes, (4) leg raise testing. Exercise induced HFpEF will be diagnosed if PAWP rises to >25mmHg.

Read the detailed description

Patients reporting to the investigators' clinic for in- and outpatient consultation and a HFA-PEFF score of 2-4 points will be recruited if their dyspnea is not sufficiently explained by other causes than HFpEF. Patients will undergo a baseline clinical exam, transthoracic echocardiography with measurement of diastolic parameters, and ECG. NYHA class will be reported, standard lab works (NTproBNP, GFR, CRP, Hb, PLT, blood gas analysis) will be taken. The number of patients with a PAWP increase in right heart catheterization (brachial access under sonographic guidance) from a resting value of \<15mmHg to >25mmHg during stress testing will be assessed across the four interventions. During bicycle ergometry (semi-supine position) spiroergometric data and gas exchange variables (cardiopulmonary exercise testing) will be co-assessed. Between the testing modalities a 10-minute break will allow hemodynamic variables to normalize.

02

Conditions studied

  • Heart Failure With Preserved Ejection Fraction

Keywords

  • diastolic stress testing
  • HFpEF
03

In context

Lead sponsor

University Hospital, Essen is the lead sponsor of 116 studies on the registry; 33 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients reporting to the investigators' in- and outpatient clinic with unsolved dyspnea through non-invasive testing and a HFA-PEFF score 2-4 points and thus an intermediate risk for HFpEF. Following the diagnostic algorithm of HFpEF invasive stress testing is indicated.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age > 18 years
  • Unclear etiology of dyspnea with non-invasive testing
  • HFA-PEFF score 2-4 points and thus an intermediate risk for HFpEF
  • Willingness to participate and obtained written consent

Exclusion criteria

Exclusion Criteria:

  • Consent for study participation not obtained
  • Age \< 18 years
  • Medical contraindications to perform right heart catheterization
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
19 participants (actual)
Patient registry
No

Groups and cohorts

  • Patients with intermediate risk for HFpEF at rest

    Patients with a HFA-PEFF score of 2-4 points and no obvious extracardiac explanation for exercise-induced dyspnea. Right heart catheterization with be performed at rest and during stress testing.

    Procedure: Right heart catheterization

Interventions

  • ProcedureRight heart catheterization

    Right heart catheterization will be performed via a brachial access under sonographic guidance and hemodynamic measurements will be performed in a semi-supine position.

06

What researchers measure

Primary outcomes

  1. PAWP increase across the four stress tests

    Number of patients with an increase of PAWP\<15mmHg at rest to \>25mmHg during stress testing.

    Time frame: 1 year

Secondary outcomes

  1. Changes of mean pulmonary artery pressure (mPAP) across the four stress tests

    mPAP changes \[mmHg\] during stress testing will be assessed.

    Time frame: 1 year

  2. Association of PAWP increase and changes of VO2peak during bicycle ergometry

    associations between PAWP \[mmHg\] and VO2peak \[ml/kg/min\] during bicycle ergometry will be assessed.

    Time frame: 1 year

  3. Changes of pulmonary vascular resistance (PVR) across the four stress tests

    PVR changes \[WU, Wood Units\] during stress testing will be assessed.

    Time frame: 1 year

07

Study locations

1 site
  • Klinik für Kardiologie und Angiologie-Westdeutsches Herz- und Gefäßzentrum Essen
    Essen, Nordrhein 45122, Germany
08

References and documents

Publications

  • Pieske B, Tschope C, de Boer RA, Fraser AG, Anker SD, Donal E, Edelmann F, Fu M, Guazzi M, Lam CSP, Lancellotti P, Melenovsky V, Morris DA, Nagel E, Pieske-Kraigher E, Ponikowski P, Solomon SD, Vasan RS, Rutten FH, Voors AA, Ruschitzka F, Paulus WJ, Seferovic P, Filippatos G. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J. 2019 Oct 21;40(40):3297-3317. doi: 10.1093/eurheartj/ehz641. PubMed 31504452 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04970953
Responsible party
Peter Lüdike (Professor of Cardiology, University Hospital, Essen) — Principal investigator
First posted
Jul 21, 2021
Start date
Aug 9, 2021
Primary completion
Jan 13, 2023
Completion
Feb 20, 2023
Last update
May 11, 2023

Study contacts

Peter Lüdike, Professor
principal investigator · University Hopsital Duisburg-Essen

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion